Prudential Financial
STML

Prudential Financial’s Stemline Therapeutics, Inc. STML Stock Holding History

Prudential Financial’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-257,730
Closed -$2.82M – 2507
2019
Q3 		$2.82M Buy
257,730
+48,010
+23% +$628K ﹤0.01% 1395
2019
Q2 		$3.21M Buy
+209,720
New +$3.03M 0.01% 1354

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Prudential Financial's STML Position: Q4 2019 in Review

Prudential Financial sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 257,730 shares — an estimated $2.82M sold.

Prudential Financial first reported a position in STML in Q2 2019 and held it in 2 quarters. The position peaked at $3.21M in Q2 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Prudential Financial reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Prudential Financial sold 257,730 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $2.82M.
  • Prudential Financial first reported a position in Stemline Therapeutics, Inc. in Q2 2019 and held it in 2 quarters.
  • Prudential Financial's Stemline Therapeutics, Inc. position peaked at $3.21M in Q2 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Prudential Financial's 13F filing for Q4 2019, filed 11 Feb 2020.